Information Provided By:
Fly News Breaks for July 19, 2019
IFRX
Jul 19, 2019 | 08:08 EDT
Raymond James analyst Steven Seedhouse disagrees with InflaRx's conclusion that data support further development of IFX-1 in hidradenitis suppurativa. The post-hoc analysis InflaRx announced last night supports the view that IFX-1 "is a zero" in hidradenitis suppurativa, Seedhouse tells investors in a research note. He keeps a Market Perform rating on InflaRx shares.